Balthaser Kevin's most recent trade in Aclaris Therapeutics Inc was a trade of 2,375 Common Stock done . Disclosure was reported to the exchange on March 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 2,375 | 93,335 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 2,375 | 2,375 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 1,100 | 0 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 1,100 | 90,960 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.99 per share. | 01 Mar 2025 | 727 | 92,608 (0%) | 0% | 2.0 | 1,447 | Common Stock |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2025 | 308,200 | 308,200 | - | - | Employee Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2025 | 88,100 | 88,100 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 14,750 | 44,250 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 14,750 | 95,676 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.48 per share. | 01 Feb 2025 | 5,816 | 89,860 (0%) | 0% | 2.5 | 14,424 | Common Stock |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 73,750 | 98,447 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 73,750 | 73,750 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2024 | 40,000 | 40,000 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.48 per share. | 31 Dec 2024 | 30,732 | 67,715 (0%) | 0% | 2.5 | 76,215 | Common Stock |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 13,200 | 26,800 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 13,200 | 85,985 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 7,500 | 15,000 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 7,500 | 75,215 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.48 per share. | 31 Dec 2024 | 5,059 | 80,926 (0%) | 0% | 2.5 | 12,546 | Common Stock |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.48 per share. | 31 Dec 2024 | 2,430 | 72,785 (0%) | 0% | 2.5 | 6,026 | Common Stock |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 1,000 | 0 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 1,000 | 24,983 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.18 per share. | 01 Sep 2024 | 286 | 24,697 (0%) | 0% | 1.2 | 337 | Common Stock |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 2,375 | 23,587 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 2,375 | 4,750 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 1,500 | 0 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 1,500 | 24,410 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 1,100 | 1,100 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 1,100 | 21,525 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.24 per share. | 01 Mar 2024 | 677 | 22,910 (0%) | 0% | 1.2 | 839 | Common Stock |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.24 per share. | 01 Mar 2024 | 427 | 23,983 (0%) | 0% | 1.2 | 529 | Common Stock |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.24 per share. | 01 Mar 2024 | 313 | 21,212 (0%) | 0% | 1.2 | 388 | Common Stock |
| Aclaris Therapeutics Inc | Balthaser Kevin | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 206,500 | 206,500 | - | - | Employee Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Balthaser Kevin | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 147,500 | 147,500 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Balthaser Kevin | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 59,000 | 59,000 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 7,500 | 22,500 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 7,500 | 22,961 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Balthaser Kevin | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.05 per share. | 01 Jan 2024 | 2,536 | 20,425 (0%) | 0% | 1.1 | 2,663 | Common Stock |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 2,375 | 5,650 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 2,375 | 7,125 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 1,500 | 6,150 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 1,500 | 1,500 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 1,475 | 2,175 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 1,475 | 0 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 1,100 | 2,200 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 1,100 | 3,275 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 12.29 per share. | 01 Mar 2023 | 1,000 | 4,650 (0%) | 0% | 12.3 | 12,289 | Common Stock |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 12.63 per share. | 01 Mar 2023 | 894 | 5,256 (0%) | 0% | 12.6 | 11,290 | Common Stock |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 105,000 | 105,000 | - | - | Employee Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Kevin Balthaser | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 30,000 | 30,000 | - | - | Restricted Stock Units |